Chang, C., et al. (2017) Pharmacogenomic Variants May Influence the Urinary Excretion of Novel Kidney Injury Biomarkers in Patients Receiving Cisplatin. International Journal of Molecular Sciences, 18, Article 1333.
https://doi.org/10.3390/ijms18071333

has been cited by the following article:

• TITLE: The Role for AVE0991 (MAS-Receptor Angiotensin II (1-7) Agonist) in Reducing Cisplatin-Induced Acute Kidney Injury on C57BL/6 Mice

  AUTHORS: Chris Mathew

  KEYWORDS: Cisplatin, Acute Kidney Injury, AKI, Cisplatin-Induced Acute Kidney Injury, Nephrotoxicity, Renal Renin Angiotensin System, RAS, AVE0991, MAS-Receptor Angiotensin II (1-7) Agonist

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.11 No.1, January 31, 2023

  ABSTRACT: Acute Kidney Injury (AKI) is a condition that causes nephrotoxicity in kidney tissues due to cisplatin-induced cancer treatments. Hence, it is proposed in this review that AVE0991 (a MAS-receptor Angiotensin II (1-7) agonist) may reduce cisplatin-induced acute kidney injury by promoting nitric oxide production.